

1 **A rapid pharmacogenomic assay to detect *NAT2* polymorphisms and guide isoniazid dosing**
2 **for tuberculosis treatment**

3
4 Renu Verma¹, Sunita Patil¹, Nan Zhang², Flora M.F. Moreira³, Marize T. Vitorio³, Andrea da S.
5 Santos³, Ellen Wallace⁴, Devasena Gnanashanmugam⁴, David Persing⁴, Rada Savic², Julio
6 Croda^{5,6}, Jason R. Andrews^{1*}

- 7
8 1. Division of Infectious Diseases and Geographic Medicine, Stanford University School of
9 Medicine, Stanford, CA, USA
10 2. Department of Bioengineering and Therapeutic Sciences, University of California, San
11 Francisco, CA, USA
12 3. Federal University of Grande Dourados, Dourados, Brazil
13 4. Cepheid Inc., Sunnyvale, California, USA
14 5. Postgraduate Program in Infectious and Parasitic Diseases, Federal University of Mato
15 Grosso do Sul, Mato Grosso do Sul, Brazil
16 6. Oswaldo Cruz Foundation Mato Grosso do Sul, Mato Grosso do Sul, Brazil

17
18 **Correspondence***

19 Jason Andrews, MD
20 Division of Infectious Diseases and Geographic Medicine
21 Biomedical Innovations Building, Room 3458
22 Stanford University School of Medicine
23 Stanford, CA 94305

24 Email: jandr@stanford.edu

25 Phone: +1 650 497 2679

26

27 **Running title:** A rapid pharmacogenomic assay for isoniazid dosing

28

29 Summary: This manuscript describes the development and validation of point-of-care multiplex
30 pharmacogenomic assay to guide personalized dosing of isoniazid for treatment or prevention of
31 tuberculosis.

32

33 **Abstract**

34 **Rationale:** Standardized weight-based dose of anti-tubercular drugs contributes to a substantial
35 incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug
36 levels achieved. Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase-2 (*NAT2*)
37 gene explain the majority of interindividual pharmacokinetic variability of isoniazid (INH).
38 However, an obstacle to implementing pharmacogenomic-guided dosing is the lack of a point-of-
39 care assay.

40 **Objectives:** To develop and test a *NAT2* classification algorithm, validate its performance in
41 predicting isoniazid clearance, and develop a prototype pharmacogenomic assay.

42 **Methods:** We trained random forest models to predict *NAT2* acetylation genotype from
43 unphased SNP data using a global collection of 8,561 phased genomes. We enrolled 48
44 pulmonary TB patients, performed sparse pharmacokinetic sampling, and tested the acetylator
45 prediction algorithm accuracy against estimated INH clearance. We then developed a cartridge-
46 based multiplex qPCR assay on the GeneXpert platform and assessed its analytical sensitivity on
47 whole blood samples from healthy individuals.

48 **Measurements and Main Results:** With a 5-SNP model trained on two-thirds of the data
49 (n=5,738), out-of-sample acetylation genotype prediction accuracy on the remaining third
50 (n=2,823) was 100%. Among the 48 TB patients, predicted acetylator types were: 27 (56.2%)
51 slow, 16 (33.3%) intermediate and 5 (10.4%) rapid. INH clearance rates were lowest in predicted
52 slow acetylators (median 19.3 L/hr), moderate in intermediate acetylators (median 41.0 L/hr) and
53 highest in fast acetylators (median 46.7 L/hr). The cartridge-based assay accurately detected all
54 allele patterns directly from 25ul of whole blood.

55 **Conclusions:** An automated pharmacogenomic assay on a platform widely used globally for
56 tuberculosis diagnosis could enable personalized dosing of isoniazid.

57 **Keywords:** tuberculosis; isoniazid; pharmacogenomic; molecular diagnostic; *NAT2*

58

59

60 INTRODUCTION

61 Despite the availability of effective chemotherapeutic regimens for treatment and prevention of
62 tuberculosis, a substantial proportion of patients experience toxicities, fail treatment or develop
63 recurrent disease (1-3). Standardized, weight-based dosing of anti-tuberculosis treatment has
64 been the conventional approach to therapy, despite mounting evidence that inter-individual
65 variability in metabolism leads to highly variable drug levels (4,5). High drug levels are strongly
66 associated with risk of toxicity, while low drug levels are a determinant of treatment failure, slow
67 response, and emergence of drug resistance. Hepatotoxicity is the most common adverse effect,
68 affecting up to 33% of patients receiving standard four-drug therapy (6) and leading to regimen
69 changes in up to 10% of patients (7). This toxicity is associated with increased costs, morbidity,
70 and occasional mortality, particularly among HIV co-infected individuals (8). Additionally, as
71 many as 3% of new tuberculosis cases experience treatment failure, and between 6-10% relapse
72 within 2 years (9,10). Pharmacokinetic variability to a single drug is associated with treatment
73 failure and acquired drug resistance (11,12). One study found that individuals with at least one
74 drug below the recommended AUC threshold had a 14-fold increased risk of poor outcomes (13)

75 More than 50 years after its introduction, isoniazid (INH) remains one of the major first line
76 drugs used to treat active and latent tuberculosis infections (14,15). There has been an increasing
77 number of genetic markers identified that predict metabolism and toxicities from various
78 antimicrobials. INH is among the most well characterized of these, with more than 80% of its
79 pharmacokinetic variability explained by mutations in the gene encoding arylamine N-
80 acetyltransferase 2 (NAT2), responsible for its metabolism in the liver (16-18). The primary step
81 in the metabolism of INH is acetylation, catalyzed by the NAT2 enzyme, resulting in the

82 formation of acetyl-INH. The NAT2 enzyme displays genetic polymorphism, and its activity is
83 expressed at highly variable levels. A high correlation between INH acetylator phenotype and
84 seven most frequent SNPs in *NAT2* gene has been demonstrated by several studies (19-22).
85 Individuals can be classified into three phenotypes—rapid, intermediate, and slow acetylators—
86 according to whether they carry polymorphisms on neither, one, or both copies of this gene,
87 respectively. Rapid acetylators typically have the lowest plasma INH concentrations, while slow
88 acetylators have high concentrations (23). A worldwide population survey on *NAT2* acetylation
89 phenotype reported that more than half of the global population are slow or rapid acetylators
90 (18). A meta-analysis of 14 studies, comprising 474 cases and 1446 controls based on *NAT2*
91 polymorphisms found that rapid acetylators are twice as likely to have microbiological failure
92 and acquired drug resistance. Additionally, a significant association has been consistently
93 observed between *NAT2* slow acetylators and the risk of anti-tuberculosis drug-induced liver
94 injury (17). Additional meta-analyses have identified a three- to four-fold increased risk of
95 hepatotoxicity among slow acetylators (24). A randomized trial of pharmacogenomic guided
96 dosing for tuberculosis treatment found that, compared with standard dosing, it reduced
97 hepatotoxicity among slow acetylators and increased treatment response at 8 weeks among rapid
98 acetylators (25)

99
100 Despite this evidence, pharmacogenomic testing and guided treatment has not entered the
101 mainstream of clinical practice for tuberculosis. Few clinical laboratories perform *NAT2*
102 genotyping, which requires detection of multiple polymorphisms and testing for heterozygous
103 allele patterns. Such testing is not widely available in resource-constrained environments where
104 the majority of tuberculosis burden falls. To address this gap, we developed an algorithm from

105 unphased SNP patterns, derived from globally representative genomic data, to predict INH
106 metabolism phenotype using fewer SNPs while retaining high accuracy. Based on the SNP
107 combination derived from this model, we further developed a prototype *NAT2* pharmacogenomic
108 (*NAT2*-PGx) assay on a commercial, automated PCR platform (GeneXpert) to detect *NAT2*
109 polymorphisms. We demonstrate that this tool can accurately predict INH clearance rates
110 directly from clinical samples and can be easily performed with minimal training and hands-on
111 time.

112

113

114 **METHODS**

115 **Datasets**

116 The datasets used to develop the NAT2 classifier was obtained from the IGSR (International
117 Genome Sample Resource, 1000 genomes project) and a meta-analysis by Sabbagh et. al (18,
118 26). Population information on the combined dataset is provided in **Supplementary Table 1**.

119

120 **NAT2 acetylator phenotype prediction classifier**

121 Phased genomes from 8,561 individuals were used and haplotypes were labeled based on seven
122 most frequent SNPs (both synonymous and non-synonymous) which are reported to affect the
123 acetylation on INH - rs1801279 (191G>A), rs1041983 (282C>T), rs1801280 (341T>C),
124 rs1799929 (481C>T), rs1799930 (590G>A), rs1208 (803A>G) and rs1799931 (857G>A) (19) in
125 the NAT2 gene, following an international consensus nomenclature (27). We then constructed an
126 unphased dataset containing only information on whether each sample was wild type for both
127 alleles, homozygous variant for both alleles, or heterozygous. We stratified the dataset by
128 geographic region and then drew a random sample from two-thirds of each stratum for a training
129 set and one third for an out-of-sample test set, to ensure geographic representativeness in the
130 training and test sets. We trained random forest models on the training set using the *caret*
131 package in R and assessed classification performance on the held-out test set. We began with a 7
132 SNP model and eliminated SNPs in sequential models according to the lowest variable
133 importance factor.

134

135 **Ethics statement**

136 The clinical study was approved by the institutional review boards of the Stanford University
137 School of Medicine and Federal University of Grande Dourados. All participants were over the
138 age of 18 and provided written informed consent. For assay optimization and validation on
139 GeneXpert cartridge, anonymized blood samples from healthy individuals were obtained from
140 Stanford blood center.

141

142 **Sample collection**

143 Sputum and plasma samples from 48 newly diagnosed patients with active pulmonary
144 tuberculosis were collected at the Federal University of Grande Dourados, Brazil. All
145 participants were treated with standardized, weight-based doses of isoniazid, rifampicin,
146 pyrazinamide and ethambutol. Plasma samples were collected at 1 hour and 8 hours after the first
147 dose and after 1 hour on day 14. Plasma drug concentrations for isoniazid and acetyl-isoniazid
148 were quantified by high-performance liquid chromatography coupled to tandem mass
149 spectrometry (HPLC-MS) as previously described (28).

150

151 **Pharmacokinetic analysis of INH clearance in tuberculosis patients**

152 The population PK analysis was performed using the non-linear mixed effects modeling
153 approach using NONMEM (version 7.4.3; ICON plc, Gaithersburg, MD, USA), PsN and R-
154 based Xpose (version 4.7 and higher) (29,30). One-compartment model with a first-order
155 absorption with a lognormal distribution for inter-individual variability (IIV) on different PK
156 parameter(s) as well as an additive and/or proportional model for the residual error were tested
157 for the base model selection. Mixture models with two or three subpopulations representing
158 different clearance rate were then evaluated. The first-order conditional estimation with

159 interaction method (FOCEI) was applied and the model-building procedure and model selection
160 was based on the log-likelihood criterion (the difference in the minimum OFV between
161 hierarchical models was assumed to be Chi-square distributed with degrees of freedom equal to
162 the difference in the number of parameters between models), goodness-of-fit plots (e.g. relevant
163 residuals against time randomly distributed around zero), and scientific plausibility of the model.
164 Visual predictive check was conducted to evaluate whether the final model with estimated fixed-
165 effect parameters and covariates adequately describe data.

166

167 **Sputum processing and host DNA extraction**

168 Spontaneously expectorated sputum samples from confirmed pulmonary tuberculosis patients
169 were collected in 10mL of guanidine thiocyanate (GTC) solution. The samples were needle
170 sheared and centrifuged at 3000 rpm for 30 min. The supernatant was collected in Trizol LS and
171 host DNA was extracted from the supernatant using a manual extraction method described
172 previously (31).

173

174 **Primers and probes for melt curve analysis**

175 We first developed single-plex melt curve assays based on molecular beacon probe chemistry for
176 five NAT2 polymorphisms. Using same primer and probe sequences, we further developed
177 multiplex NAT2-PGx assay compatible on GeneXpert platform. Three sets of primers and five
178 molecular beacon probes spanning the *NAT2* gene were used. Primers and probes were designed
179 using Beacon Designer (Premier Biosoft International, Palo, CA; version 8). A list of primers
180 and probes sequences with their corresponding fluorophores and quenchers is provided in

181 **Supplementary Table 2.**

182 **NAT2-genotyping on pulmonary TB samples**

183 Host genomic DNA extracted from 48 sputum samples from TB positive patients was used to
184 perform single-plex qPCR assays developed in-house. The assays were validated using TaqMan
185 commercial genotyping assays (NAT2 TaqMan® SNP Genotyping Assays, Applied
186 Biosystems). The genotyping was performed on StepOne Plus Real Time PCR (Applied
187 Biosystems). The NAT2-genotypes derived from the assays were used to predict INH acetylator
188 phenotype by our 5-SNP model.

189

190 **Automated NAT2-PGx Multiplex PCR and melt curve analysis**

191 We combined the five single-plex NAT2 melt curve assays validated on TB samples into one
192 and developed a multiplex assay (NAT2-PGx) on the Flexible Cartridge (Flex cart-01, Cepheid)
193 platform. Flex cart allows automated DNA extraction from whole blood followed by PCR
194 amplification and melt curve analysis to detect SNPs in *NAT2* gene in a single run. NAT2-PGx
195 assay was performed on a GeneXpert IV instrument using GeneXpert Dx 4.8 software (Cepheid,
196 Sunnyvale). Briefly, 100ul of whole blood was mixed with 900ul of GeneXpert lysis buffer for
197 whole blood (Cepheid), incubated for 2 min at room temperature and loaded into sample
198 preparation chamber of the flex cart for automated DNA extraction. A 70ul of PCR mastermix
199 was simultaneously loaded in the PCR reaction chamber of the flex cart-01. PCR and melt
200 conditions were optimized using mastermix prepared in house.

201 We validated the multiplex assay on blood samples from 20 healthy individuals. The accuracy of
202 multiplex NAT2-PGx assay in SNP calling was subsequently validated by Sanger sequencing
203 (see methods). We assessed analytical sensitivity of the assay and robustness to input blood
204 volume by performing it on varying volumes of whole blood (200 ul, 100 ul, 50 ul, 25 ul) and

205 comparing the T_m results and standard deviation for each position across blood volumes.
206 Additional details on the qPCR run method and melt curve analysis is provided in an online data
207 supplement.

208

209 **RESULTS**

210 **SNP selection and development of acetylation prediction model**

211 Complete phased data for the seven polymorphisms that define acetylation haplotypes were
212 available for 8,561 individuals from 59 populations. The dataset contains 3,573 (41.7%)
213 individuals with a slow genotype, 3,428 (40.0%) individuals with an intermediate genotype, and
214 1,560 (18.2%) individuals with a rapid genotype (See **Table 1**). The highest proportion of rapid
215 acetylators were in East Asia (40%), and three regions had prevalence of slow acetylator
216 phenotypes over 50% (Central and South Asia, Europe and North Africa). We used these phased
217 allele data to select SNPs for inclusion in an assay measuring unphased SNPs. Using a random
218 forest model trained on two thirds of the data (n=5,738), out-of-sample phenotype prediction
219 accuracy from unphased data on the remaining one third (n=2,823) was 100% for models using
220 7, 6 or 5 SNPs. With 4 SNPs, prediction accuracy was 98.0% (95% CI: 97.4-98.5%), and a 3
221 SNP model had similar performance (98.0%; 95% CI: 97.4-98.4%) (**Table 2**). However, both of
222 these models performed poorly on data from Sub-Saharan Africa (4 SNP model accuracy:
223 82.5%, 95% CI: 78.1-86.4%); 3 SNP model accuracy: 81.3%, 95% CI: 76.8-85.3%). Based on
224 these results, we selected the 5 SNP model (191G>A, 282C>T, 341T>C, 590G>A and 857G>A)
225 to take forward for clinical validation and diagnostic development.

226

227 **Genotype correlation with isoniazid clearance in patients with tuberculosis**

228 We enrolled a cohort of 48 patients with newly diagnosed pulmonary tuberculosis and collected
229 plasma at 1 hour and 8 hours after dose on day 1 and at 1 hour after dose on day 14. To detect
230 five *NAT2* polymorphisms identified by our classifier, we performed single-plex melt curve
231 qPCR assays developed in-house using host DNA extracted from sputum samples. Additionally,
232 we used commercial 7-SNP single-plex genotyping assays and compared the results with 5-SNP
233 single-plex PCR to validate the melt curve accuracy in SNP detection. There was 100%
234 concordance in terms of SNP detection between single-plex melt curve and commercial 7-SNP
235 assays. Of the 48 individuals for whom *NAT2* genotypes were profiled, DNA-probe hybrid
236 melting temperature difference (ΔT_m) ($^{\circ}\text{C}$) between wild-type and mutant alleles for positions
237 191, 282, 341, 590 and 857 were found to be 4.38, 4.04, 2.40, 3.63 and 3.68 respectively. Both
238 mutant and wild type probes had a minimum 2.40°C T_m difference which allowed SNP calling
239 with high accuracy (**Table 3**).

240
241 We further predicted phenotypes from 5-SNP using the algorithm described above as well as a
242 publicly available tool (NAT2Pred) (32), which uses a 6 SNP model that excludes rs1801279
243 (191G>A) and includes other two sites from 7-SNP model- rs1799929 (481C>T) and rs1208
244 (803A>G) when compared with our 5-SNP model. Among the 48 participants, predicted
245 acetylator types from the 5 SNP assay were: 27 (56.2%) slow, 16 (33.3%) intermediate and 5
246 (10.4%) rapid. NAT2Pred classified 4 samples as intermediate that were classified as rapid (n=1)
247 or slow (n=3) by the 5 SNP classifier. Among those classified as slow by the 5 SNP classifier
248 and intermediate by NAT2Pred, acetyl-INH to INH ratios at 8 hours were 0.61, 0.38, 0.41,
249 consistent with slow acetylation (median: 0.76, range 0.36-1.55) rather than intermediate
250 acetylation (median 6.67, range 3.32-22.21) and suggesting misclassification by NAT2Pred. The

251 sample classified as intermediate by NAT2Pred and rapid by the 5 SNP classifier had an acetyl-
252 INH to INH ratio of 9.8, which fell between the median values, and within both ranges, for
253 intermediate and rapid acetylators (range 8.09 - ∞) (**Supplementary Table-3**). Phenotypes
254 predicted by the 5 SNP classifier were strongly predictive of INH acetylation and clearance
255 (**Figure 1a and 1b**). INH clearance rates were lowest in slow acetylators (median 19.3 L/hr),
256 moderate in intermediate acetylators (median 41.0 L/hr) and highest in fast acetylators (median
257 46.7 L/hr).

258

259 **Development of an automated pharmacogenomic assay**

260 We validated the NAT2-PGx assay on 20 whole blood samples from healthy individuals. The
261 hands-on time for the cartridge preparation per sample was 5 minutes followed by 140 minutes
262 for overall run that included automated DNA extraction (**Figure 2**). Mutant, wild-type and
263 heterozygous alleles were manually called based on peak patterns and T_m values detected in
264 melt curves. Negative derivative transformed melt curves from five *NAT2* gene polymorphisms
265 are shown in **Figure 3**. The assay detected all polymorphisms with 100% accuracy (average SD
266 in T_m across all probes = 0.34°C) compared with Sanger sequencing. The *NAT2* genotypes
267 corresponding to 20 blood samples covered all three categories - mutant, wild-type and
268 heterozygous for five *NAT2* positions except for NAT2-191 for which all samples were all wild-
269 type. The 191G>A mutation is highly prevalent in African and African-American populations
270 and is less common in other populations (33). Among the 20 samples, predicted acetylator types
271 using the 5-SNP classifier were: 8 (40%) slow, 10 (50%) intermediate and 2 (10%) rapid
272 (**Supplementary Table 4a**).

273

274 We further assessed the analytic performance of the NAT2-PGx assay at lower sample volumes.
275 Our assay could accurately detect all melt peaks with as low as 25ul of sample volume. The
276 variability in T_m from five *NAT2* probes for sample volumes 200ul-25ul is shown in **Figure 4**.
277 *NAT2* polymorphisms were accurately detected at all volumes (**Supplementary Table 4b**) and
278 demonstrated robustness to variation in input volume.
279

280 **DISCUSSION**

281 Despite availability of effective treatment for drug-sensitive tuberculosis, a substantial
282 proportion of population encounters drug associated toxicity or treatment failure, much of which
283 could be averted through dosing guided by genetic markers of drug metabolism (34). We
284 previously found that pharmacogenomic guided dosing of isoniazid could be highly cost-
285 effective in low- and middle-income countries (35). A major barrier to its implementation has
286 been the lack of a simple, scalable assay that could be used at points of care where tuberculosis is
287 treated in resource-constrained settings. To address this gap, we used globally representative
288 genomic data to identify patterns of 5 SNPs that enable accurate prediction of isoniazid
289 acetylator phenotype, validating this with pharmacokinetic data of patients receiving tuberculosis
290 treatment. We then developed a prototype automated pharmacogenomic assay on the GeneXpert
291 platform, which is widely available globally but had never been applied to pharmacogenomics.
292 We found that this assay could robustly distinguish wild type, mutant and heterozygous alleles
293 from a range of blood volumes as low as 25 ul, making it suitable for use with venous blood
294 samples or finger-stick blood samples. The assay requires minimal hands-on time for sample
295 preparation, which would facilitate its use in resource-constrained settings.

296
297 An earlier model (“NAT2Pred”) predicted NAT2 acetylation phenotype from unphased genomic
298 data; however, it had moderate error rates in distinguishing intermediate from rapid acetylators
299 (33). Moreover, error rates among individuals from Sub-Saharan Africa were 14%, in part due to
300 the exclusion of the G191A (R64Q) SNP, common to the NAT2 *14 allele cluster, which is
301 frequent in Africans and African-Americans, but virtually absent in Caucasian, Indian, and
302 Korean populations (36). A recent study using the set of 6 NAT2 SNPs included in NAT2Pred,

303 but not including G191A, found no correlation between *NAT2* genotype and INH acetylation
304 phenotype in HIV-infected, Zulu individuals with culture-confirmed tuberculosis in Durban,
305 South Africa (37), underscoring the importance of including this SNP in genotype predictions in
306 this region.

307
308 Indeed, ethnic differences in SNP frequencies are responsible for the differences in frequency of
309 rapid, intermediate and slow acetylators *NAT2* haplotypes (18, 23). We trained our SNP classifier
310 with globally representative data, which resulted in the selection and inclusion of the G191A
311 SNP in our model and assay. This is particularly important as Sub-Saharan Africa bears a
312 substantial burden of tuberculosis disease and mortality as well as HIV co-infection, which is
313 independently associated with greater pharmacokinetic variability and tuberculosis treatment
314 toxicity (38, 39).

315
316 The association between acetylation polymorphisms and INH metabolism was first demonstrated
317 in 1959, and their importance was well characterized in subsequent decades through phenotypic
318 descriptions (40-42). Subsequent genotypic descriptions confirmed that *NAT2* polymorphisms
319 predicted INH early bactericidal activity, and clinical outcomes including hepatotoxicity, relapse
320 and acquisition of drug resistance. Further dosing studies demonstrated that provision of lower
321 doses to slow acetylators and higher doses to rapid acetylators could achieve target
322 concentrations (43). One randomized trial of pharmacogenomic-guided dosing of INH during
323 active tuberculosis treatment found that it significantly reduced toxicities (among slow
324 acetylators) and treatment non-response (among rapid acetylators). Taken together, the evidence
325 for pharmacogenomic guided dosing to achieve consistent drug levels and improve clinical

326 outcomes is strong. Automated, easy-to-use assays could enable pharmacogenomic guided
327 isoniazid dosing in resource constrained settings, where a substantial burden of the world's
328 tuberculosis occurs.

329 The findings of this study are subject to several limitations. We tested the assays on 48
330 individuals with active tuberculosis and 20 healthy individuals with a diverse representation of
331 polymorphisms, but the number of participants with G191A mutations was limited (n=5). A
332 larger validation study involving testing on whole blood, including from finger stick capillary
333 blood, is needed to assess real-world performance of this assay under field conditions. Due to
334 unavailability of whole blood samples from TB patients, we used sputum samples to extract host
335 DNA for genotyping. Further studies should also investigate testing on non-invasive samples
336 including sputum, saliva or oral swabs, from which DNA is abundant. Second, we focused on
337 *NAT2* polymorphisms, as they explain majority of interindividual pharmacokinetic variability,
338 though polymorphisms in several other genes have been associated with hepatotoxicity.
339 However, these associations have been comparatively modest and somewhat inconsistent (44-
340 45). We focused on INH and did not include other important tuberculosis drugs, such as
341 rifampicin. The evidence base for pharmacogenomic markers predicting rifampin
342 pharmacokinetics is less robust, and findings concerning clinical outcomes such as toxicities or
343 treatment response are limited (46-49). However, given the importance of this drug class in
344 treatment of active and latent tuberculosis, and emerging evidence supporting greater efficacy of
345 higher doses of rifampin, further investigation of pharmacogenomic markers in rifampicin is
346 needed. Future assays may include polymorphisms influencing rifampicin metabolism to further
347 optimize treatment of tuberculosis.

348

349 Since the demonstration of the efficacy of six month, short-course chemotherapy in 1979,
350 standardized treatment for drug susceptible tuberculosis using weight-based doses has remained
351 essentially unchanged. Additionally, INH remains a major component of regimens for treatment
352 of latent tuberculosis, which is recommended by the WHO for young children, HIV-infected
353 individuals and household contacts of tuberculosis cases (50). More than half the world's
354 population have slow or rapid acetylation phenotypes, which put them at risk for excessive drug
355 levels resulting in drug toxicities or insufficient drug levels putting them at risk of acquired drug
356 resistance or disease relapse. Dose adjustment based on NAT2 acetylation genotyping can
357 achieve consistent, target drug levels and reduce the incidence of poor clinical outcomes. We
358 developed a prototype automated, cartridge-based assay that can reliably predict acetylation
359 phenotype directly from as low as 25 ul of whole blood. By developing this for the GeneXpert
360 platform, which is widely used in low- and middle-income countries for tuberculosis diagnosis,
361 this assay could make personalized tuberculosis treatment dosing available in resource-
362 constrained settings. Further studies are needed to evaluate its accuracy and clinical impact in
363 real-world clinical settings.

364

365

366 **Funding**

367 FleXcartridges and technical support for their use were provided by Cepheid. This study was
368 supported by the Institute for Immunity, Transplantation, and Infection and the Department of
369 Medicine at Stanford University.

370

371 **Data availability**

372 Data supporting the findings of this manuscript are available in the Supplementary Information
373 files or from the corresponding author upon request.

374

375 **Acknowledgements**

376 We thank Veronique Dartois for performing the plasma drug level assays.

377

378 **Author contributions**

379 JRA and RV conceived of the study. RV, JC, and JRA designed the experiments. RV, SP,

380 FMM, MTV, ASS and JC collected data. RV, NZ, RS and JRA analyzed data. EW, DG and DP

381 provided technical guidance on the assay development. RV and JRA wrote the first draft of the

382 manuscript, and all authors contributed to the final version.

383 **Conflicts of Interest**

384 JRA and RV are named co-inventors on a provisional patent (Application number 62/991,477) for

385 a *NAT2* pharmacogenomic assay.

386 **References**

- 387 1. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F,
388 Phillips PP, Nunn AJ; REMoxTB Consortium. Four-month moxifloxacin-based regimens for
389 drug-sensitive tuberculosis. *N Engl J Med.* 2014 Oct 23;371(17):1577-87. doi:
390 10.1056/NEJMoa1407426. Epub 2014 Sep 7.
- 391 2. Merle CS, Fielding K, Sow OB, Ginafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye
392 E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis
393 C, Lapujade O, Olliaro PL, Lienhardt C; OFLOTUB/Gatifloxacin for Tuberculosis Project. A
394 four-month gatifloxacin-containing regimen for treating tuberculosis. *N Engl J Med.* 2014
395 Oct 23;371(17):1588-98. doi: 10.1056/NEJMoa1315817. Erratum in: *N Engl J Med.* 2015
396 Apr 23;372(17):1677.
- 397 3. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M,
398 Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L,
399 Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD,
400 Butcher PD, Mitchison DA; RIFAQUIN Trial Team. High-dose rifapentine with
401 moxifloxacin for pulmonary tuberculosis. *N Engl J Med.* 2014 Oct 23;371(17):1599-608.
- 402 4. Pratt VM, Everts RE, Aggarwal P, Beyer BN, Broeckel U, Epstein-Baak R, Hujsak P,
403 Kornreich R, Liao J, Lorier R, Scott SA, Smith CH, Toji LH, Turner A, Kalman LV.
404 Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes:
405 A GeT-RM Collaborative Project. *J Mol Diagn.* 2016 Jan;18(1):109-23.
- 406 5. García-Martín E. Interethnic and intraethnic variability of NAT2 single nucleotide
407 polymorphisms. *Curr Drug Metab.* 2008 Jul;9(6):487-97.

- 408 6. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and
409 pyrazinamide in patients hospitalized for pulmonary tuberculosis. *Eur Respir J*. 1996
410 Oct;9(10):2026-30.
- 411 7. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA,
412 Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR; ATS
413 (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee.
414 An official ATS statement: hepatotoxicity of antituberculosis therapy. *Am J Respir Crit*
415 *Care Med*. 2006 Oct 15;174(8):935-52.
- 416 8. Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Kenyon C, Maartens G, Wilkinson
417 RJ, Meintjes G. Burden of antituberculosis and antiretroviral drug-induced liver injury at a
418 secondary hospital in South Africa. *S Afr Med J*. 2012 Mar 2;102(6):506-11.
- 419 9. Luzze H, Johnson DF, Dickman K, Mayanja-Kizza H, Okwera A, Eisenach K, Cave MD,
420 Whalen CC, Johnson JL, Boom WH, Joloba M; Tuberculosis Research Unit. Relapse more
421 common than reinfection in recurrent tuberculosis 1-2 years post treatment in urban Uganda.
422 *Int J Tuberc Lung Dis*. 2013 Mar;17(3):361-7.
- 423 10. Romanowski K, Balshaw RF, Benedetti A, Campbell JR, Menzies D, Ahmad Khan F,
424 Johnston JC. Predicting tuberculosis relapse in patients treated with the standard 6-month
425 regimen: an individual patient data meta-analysis. *Thorax*. 2019 Mar;74(3):291-297.
- 426 11. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the
427 pharmacokinetic variability hypothesis for acquired drug resistance and failure of
428 antituberculosis therapy. *Clin Infect Dis*. 2012 Jul;55(2):169-77.
- 429 12. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid
430 bactericidal activity and resistance emergence: integrating pharmacodynamics and

- 431 pharmacogenomics to predict efficacy in different ethnic populations. *Antimicrob Agents*
432 *Chemother.* 2007 Jul;51(7):2329-36.
- 433 13. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug
434 concentrations predictive of pulmonary tuberculosis outcomes. *J Infect Dis.* 2013 Nov
435 1;208(9):1464-73.
- 436 14. Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current
437 standards and recent advances. *Insights from the Society of Infectious Diseases Pharmacists.*
438 *Pharmacotherapy.* 2009 Dec;29(12):1468-81
- 439 15. Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis
440 Infection: Recommendations from the National Tuberculosis Controllers Association and
441 CDC, 2020. *MMWR Recomm Rep* 2020;69(No. RR-1):1–11.
- 442 16. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M,
443 Cascorbi I, Doroshenko O, Sörgel F, Fuhr U. Should we use N-acetyltransferase type 2
444 genotyping to personalize isoniazid doses? *Antimicrob Agents Chemother.* 2005
445 May;49(5):1733-8.
- 446 17. Du H, Chen X, Fang Y, Yan O, Xu H, Li L, Li W, Huang W. Slow N-acetyltransferase 2
447 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. *Mol*
448 *Biol Rep.* 2013 May;40
- 449 18. Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide
450 distribution of NAT2 diversity: implications for NAT2 evolutionary history. *BMC Genet.*
451 2008 Feb 27;9:21.

- 452 19. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to
453 anti-tuberculosis drug-induced liver injury: a meta-analysis. *Int J Tuberc Lung Dis.* 2012
454 May;16(5):589-95.
- 455 20. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der
456 Walt BJ, Donald PR, van Jaarsveld PP. Trimodality of isoniazid elimination: phenotype and
457 genotype in patients with tuberculosis. *Am J Respir Crit Care Med.* 1997 May;155(5):1717-
458 22.
- 459 21. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F.
460 Distribution and concordance of N-acetyltransferase genotype and phenotype in an
461 American population. *Cancer Epidemiol Biomarkers Prev.* 1999 Aug;8(8):683-92.
- 462 22. Mrozikiewicz PM, Cascorbi I, Brockmöller J, Roots I. Determination and allelic allocation
463 of seven nucleotide transitions within the arylamine N-acetyltransferase gene in the Polish
464 population. *Clin Pharmacol Ther.* 1996 Apr;59(4):376-82.
- 465 23. Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer
466 rapid, intermediate and slow acetylator phenotypes. *Pharmacogenomics.* 2012 Jan;13(1):31-
467 41.
- 468 24. Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available
469 information. *Am Rev Respir Dis.* 1992 Feb;145(2 Pt 1):494-7.
- 470 25. Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T,
471 Kamimura S, Fujio Y, Kawase I; Pharmacogenetics-based tuberculosis therapy research
472 group. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early
473 treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized

- 474 controlled trial for pharmacogenetics-based therapy. *Eur J Clin Pharmacol.* 2013
475 May;69(5):1091-101.
- 476 26. McInnes G and Russ A. Drug Response Pharmacogenetics for 200,000 UK Biobank
477 Participants.
- 478 27. *Database of arylamine N-acetyltransferases* (<http://nat.mbg.duth.gr>)
- 479 28. Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, Chen C, Kaya F,
480 Weiner DM, Chen PY, Song T, Lee M, Shim TS, Cho JS, Kim W, Cho SN, Olivier KN,
481 Barry CE 3rd, Dartois V. The association between sterilizing activity and drug distribution
482 into tuberculosis lesions. *Nat Med.* 2015 Oct;21(10):1223-7.
- 483 29. Beal SL. Et al. NONMEM 7.4 Users Guides. (1989– 2019). ICON plc, Gaithersburg, MD.
484 <https://nonmem.iconplc.com/nonmem744>
- 485 30. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)--a Perl module for
486 NONMEM related programming. *Comput Methods Programs Biomed.* 2004 Aug;75(2):85-
487 94.
- 488 31. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and
489 proteins from cell and tissue samples. *Biotechniques.* 1993 Sep;15(3):532-4, 536-7. PMID:
490 7692896.
- 491 32. Kuznetsov IB, McDuffie M, Moslehi R. A web server for inferring the human N-
492 acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype. *Bioinformatics.*
493 2009 May 1;25(9):1185-6.
- 494 33. Sabbagh A, Darlu P, Vidaud M. Evaluating NAT2PRED for inferring the individual
495 acetylation status from unphased genotype data. *BMC Med Genet.* 2009 Dec 31;10:148.

- 496 34. Ramachandran G, Swaminathan S. Role of pharmacogenomics in the treatment of
497 tuberculosis: a review. *Pharmgenomics Pers Med.* 2012;5:89-98
- 498 35. Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, Andrews JR. Cost-
499 effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of
500 Active Tuberculosis. *Clin Infect Dis.* 2020 Dec 15;71(12):3136-3143.
- 501 36. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2)
502 genetic diversity and traditional subsistence: a worldwide population survey. *PLoS One.*
503 2011 Apr 6;6(4):e18507.
- 504 37. Mthiyane T, Millard J, Adamson J, Balakrishna Y, Connolly C, Owen A, Rustomjee R,
505 Dheda K, McIlleron H, Pym AS. *N*-Acetyltransferase 2 Genotypes among Zulu-Speaking
506 South Africans and Isoniazid and *N*-Acetyl-Isoniazid Pharmacokinetics during
507 Antituberculosis Treatment. *Antimicrob Agents Chemother.* 2020 Mar 24;64(4):e02376-19.
- 508 38. van Oosterhout JJ, Dzinjalama FK, Dimba A, Waterhouse D, Davies G, Zijlstra EE,
509 Molyneux ME, Molyneux EM, Ward S. Pharmacokinetics of Antituberculosis Drugs in
510 HIV-Positive and HIV-Negative Adults in Malawi. *Antimicrob Agents Chemother.* 2015
511 Oct;59(10):6175-80.
- 512 39. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Variability in the
513 population pharmacokinetics of isoniazid in South African tuberculosis patients. *Br J Clin*
514 *Pharmacol.* 2011 Jul;72(1):51-62.
- 515 40. Iselius L, Evans DA. Formal genetics of isoniazid metabolism in man. *Clin Pharmacokinet.*
516 1983 Nov-Dec;8(6):541-4.
- 517 41. Evans DA. Genetic variations in the acetylation of isoniazid and other drugs. *Ann N Y Acad*
518 *Sci.* 1968 Jul 31;151(2):723-33.

- 519 42. Evans DA. An improved and simplified method of detecting the acetylator phenotype. J
520 Med Genet. 1969 Dec;6(4):405-7.
- 521 43. Naidoo A, Chirehwa M, Ramsuran V, McIlleron H, Naidoo K, Yende-Zuma N, Singh R,
522 Ncgapu S, Adamson J, Govender K, Denti P, Padayatchi N. Effects of genetic variability on
523 rifampicin and isoniazid pharmacokinetics in South African patients with recurrent
524 tuberculosis. *Pharmacogenomics*. 2019 Mar;20(4):225-240.
- 525 44. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the
526 population pharmacokinetics of pyrazinamide in South African tuberculosis patients. *Eur J*
527 *Clin Pharmacol*. 2006 Sep;62(9):727-35.
- 528 45. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS. NAT2 and CYP2E1
529 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. *Int J*
530 *Tuberc Lung Dis*. 2010 May;14(5):622-6.
- 531 46. Roy B, Ghosh SK, Sutradhar D, Sikdar N, Mazumder S, Barman S. Predisposition of
532 antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and
533 haplotype in pediatric patients. *J Gastroenterol Hepatol*. 2006 Apr;21(4):784-6.
- 534 47. Simon T, Becquemont L, Mary-Krause M, de Waziers I, Beaune P, Funck-Brentano C,
535 Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine
536 hepatotoxicity. *Clin Pharmacol Ther*. 2000 Apr;67(4):432-7.
- 537 48. Strange RC, Jones PW, Fryer AA. Glutathione S-transferase: genetics and role in
538 toxicology. *Toxicol Lett*. 2000 Mar 15;112-113:357-63.
- 539 49. Mukonzo JK, Kengo A, Kutesa B, Nanzigu S, Pohanka A, McHugh TD, Zumla A, Aklillu
540 E. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-

541 rifampicin sensitivity among Ugandan patients. *Trans R Soc Trop Med Hyg.* 2020 Feb
542 7;114(2):107-114.

543 50. Haley CA. Treatment of Latent Tuberculosis Infection. *Microbiol Spectr.* 2017 Apr;5(2).

544
545 **Figure 1. Predicted NAT2 phenotype from sputum samples and associated acetylation ratio**
546 **and isoniazid clearance rates from patients receiving tuberculosis treatment.** The (a) 8 hour
547 acetyl-INH to INH ratio and (b) isoniazid clearance rates, according to acetylation phenotype
548 predicted from 5 SNPs, measured in sputum samples from 48 patients receiving treatment for
549 active tuberculosis.

550
551 **Figure 2. Schemata for the automated NAT2 Pharmacogenomic assay.** 1-2 drops of blood is
552 collected in an Eppendorf tube and mixed with lysis buffer to a total of 1 ml, which is then
553 loaded onto a GeneXpert Flex01 cartridge and placed into a GeneXpert instrument for automated
554 DNA extraction, qPCR and meltcurve analysis. Allele patterns for each of the 5 SNPs are
555 determined by Tm analysis, and the resulting data are used to predict acetylator phenotype.

556
557 **Figure 3. Negative derivative transformed melt curves for the five NAT2 gene**
558 **polymorphisms.** The shift in melt curve temperature is observed during a nucleotide exchange.
559 Molecular beacon probes are first hybridized and then melted off of their *NAT2* target amplicon.
560 The melt curves indicate wild type alleles at positions 191(red), 341(green) and 857 (orange);
561 and mutant alleles at positions 282(Blue) and 590(Purple).

562
563 **Figure 4. Effect of whole blood sample volume on melting temperature for wild type and**
564 **mutant alleles at 5 positions in NAT2:** *NAT2* polymorphisms were accurately detected at all

565 volumes with sufficient different in melting temperature (T_m) to distinguish wild type from
566 mutant alleles. None of the individuals in this dataset had mutations at position 191.
567

568 **Table 1. Summary of populations included in genomic analysis and their acetylation**
569 **genotypes.**

570

Region	Number of individuals	Acetylation Genotype, n (%)		
		Slow	Intermediate	Rapid
Americas	1,112	432 (39%)	463 (42%)	217 (20%)
Central and South Asia	588	355 (60%)	198 (34%)	35 (6%)
East Asia	2,308	340 (15%)	1049 (45%)	919 (40%)
Europe	3,458	1966 (57%)	1249 (36%)	243 (7%)
North Africa	44	30 (68%)	10 (23%)	4 (9%)
sub-Saharan Africa	1,051	450 (43%)	459 (44%)	142 (14%)
Total	8,561	3573 (42%)	3428 (40%)	1560 (18%)

571

572

573 **Table 2. Out-of-sample prediction accuracy of unphased NAT2 SNP data for acetylation**

574 **phenotype in random forest models.** Models were trained with 5,738 individuals and tested on

575 2,823 individuals. Sens: sensitivity. Spec: specificity.

576

NAT2 SNP Positions	SNP number	Accuracy	95% CI	Sens. Rapid	Spec. Rapid	Sens. Slow	Spec Slow
191, 282, 341, 481, 590, 803, 857	7	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
191, 282, 341, 481, 590, 857	6	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
191, 282, 341, 590, 857	5	1.000	(0.999-1.000)	1.000	1.000	1.000	1.000
282, 341, 590, 857	4	0.978	(0.972-0.983)	0.996	0.988	0.969	0.999
341, 590, 847	3	0.976	(0.970-0.982)	1.000	0.986	0.967	1.000
341, 590	2	0.852	(0.838-0.865)	1.000	0.889	0.832	1.000

577

578

579

580

581 **Table 3. Melting temperature (T_m) values for five NAT2 polymorphisms derived from**
 582 **DNA-probe hybrid melts using single-plex assays validated on 48 pulmonary TB patients**

583

	Mutant	Wild type	Het	Mutant	Wild type	
NAT2 SNP position	Total samples analyzed	Total samples analyzed	Total samples analyzed	T _m ± SD	T _m ± SD	ΔT _m (WT-MT)
191	0	44	5	66.3 ± 0.28	61.92 ± 0.68	4.38
282	6	24	19	62.81 ± 0.40	66.85 ± 0.34	4.04
341	12	23	14	66.30 ± 0.48	68.70 ± 0.38	2.40
590	0	35	14	68.0 ± 0.28	64.37 ± 0.28	3.63
857	1	41	7	66.4 ± 0.11	62.72 ± 0.29	3.68

584 SD: Standard deviation, ΔT_m: DNA-probe hybrid melting temperature difference, WT: Wild
 585 type, MT: mutant

586

587 **Supplementary Table 1.** Population information on the dataset used to develop the 5-SNP
588 classifier.

589

590 **Supplementary Table 2.** List of primers and probes sequences for multiplex assay with their
591 corresponding fluorophores and quenchers

592

593 **Supplementary Table 3.** *NAT2* polymorphism profiles of 48 pulmonary TB patients detected
594 from 5-SNP and 7-SNP genotyping assays. Acetylator phenotypes predicted from 5-SNP, 6-SNP
595 and 7-SNP classifiers and plasma INH and acetyl-INH levels recorded at various time-points.

596

597 **Supplementary Table 4. (a)** *NAT2* genotype of whole blood samples (n=20) analyzed on 5-
598 plex *NAT2*-PGx assay and validated on Sanger sequencing. **(b)** *NAT2* genotypes of ten whole
599 blood samples analyzed using 200ul, 100ul, 50ul and 25ul samples

600


601 **At a Glance Commentary**

602 **Scientific Knowledge on the Subject:** Standardized weight-based dose of isoniazid (INH) may
603 result in variable drug levels in individuals leading to drug-induced toxicities, treatment failure
604 and relapse. Polymorphisms in the *NAT2* gene explain the majority of interindividual
605 pharmacokinetic variability of INH. Pharmacogenomic guided dosing may improve treatment
606 outcomes, but scalable assays are not available.


607 **What This Study Adds to the Field:** Earlier *NAT2* acetylation prediction algorithms had
608 diminished accuracy in African populations by failing to include a common polymorphism. We
609 developed an algorithm on globally representative data that predicted acetylation genotype with
610 100% accuracy using 5 unphased SNPs. We tested the accuracy of this acetylator prediction
611 algorithm against INH clearance rates in 48 pulmonary TB patients and found very strong high
612 correlation. We then developed a cartridge-based multiplex assay for these 5 SNPs on the
613 GeneXpert platform that can accurately detect *NAT2* genotype from 25ul whole blood. Because
614 this platform is widely used in low- and middle-income countries for tuberculosis diagnosis, this
615 assay could make personalized isoniazid dosing available in resource-constrained settings.

616


A



B




① **Sample collection**



Collect 1-2 drops of whole blood (approx. 50ul)

② **Whole blood pretreatment**



Mix 950ul lysis buffer, vortex for 2 sec and incubate at RT for 2min

③ **Flex cart01 preparation**



Pipette 1ml pretreated sample and 70ul PCR mastermix into the cartridge


④ **Automated DNA extraction & qPCR**



Total run time= 140min


Load the cartridge in the GeneXpert machine and start the run

⑤ **Data acquisition**



Acquire melt curve data for NAT2 gene polymorphism detection

⑥ **INH acetylator phenotype prediction**



INH acetylator phenotype:
--Rapid acetylator
--Intermediate acetylator
--Slow acetylator

Upload NAT2 polymorphism data on phenotype prediction algorithm

